- Home
- MVO vs TLSA Comparison
MVO vs TLSA Comparison
Compare MVO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVO
- TLSA
- Stock Information
- Founded
- MVO 2006
- TLSA 2013
- Country
- MVO United States
- TLSA United Kingdom
- Employees
- MVO N/A
- TLSA N/A
- Industry
- MVO Oil & Gas Production
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- MVO Energy
- TLSA Health Care
- Exchange
- MVO Nasdaq
- TLSA Nasdaq
- Market Cap
- MVO 94.2M
- TLSA 87.8M
- IPO Year
- MVO N/A
- TLSA 2000
- Fundamental
- Price
- MVO $8.18
- TLSA $0.78
- Analyst Decision
- MVO
- TLSA
- Analyst Count
- MVO 0
- TLSA 0
- Target Price
- MVO N/A
- TLSA N/A
- AVG Volume (30 Days)
- MVO 55.1K
- TLSA 347.9K
- Earning Date
- MVO 01-01-0001
- TLSA 12-31-2024
- Dividend Yield
- MVO 17.46%
- TLSA N/A
- EPS Growth
- MVO N/A
- TLSA N/A
- EPS
- MVO 1.46
- TLSA N/A
- Revenue
- MVO N/A
- TLSA N/A
- Revenue This Year
- MVO N/A
- TLSA N/A
- Revenue Next Year
- MVO N/A
- TLSA N/A
- P/E Ratio
- MVO $7.29
- TLSA N/A
- Revenue Growth
- MVO N/A
- TLSA N/A
- 52 Week Low
- MVO $8.85
- TLSA $0.41
- 52 Week High
- MVO $13.95
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- MVO 36.39
- TLSA 33.06
- Support Level
- MVO $8.36
- TLSA $0.73
- Resistance Level
- MVO $8.38
- TLSA $1.07
- Average True Range (ATR)
- MVO 0.33
- TLSA 0.09
- MACD
- MVO -0.04
- TLSA -0.02
- Stochastic Oscillator
- MVO 13.16
- TLSA 12.86
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These oil and gas properties include producing oil and gas wells.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.